RPID RAPID MICRO BIOSYSTEMS INC

Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024

Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024

LOWELL, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2024 financial results prior to the market open on Friday, May 3, 2024.

In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 3, 2024. The live webcast will be accessible on the Company’s website and will be available for replay for one year from the webcast date.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual MQC testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands.

For more information, please visit  or follow the Company on X (formerly known as Twitter) at  or on .



Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
 

Media Contact:
 
EN
18/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RAPID MICRO BIOSYSTEMS INC

 PRESS RELEASE

Rapid Micro Biosystems to Announce First Quarter 2024 Financial Result...

Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024 LOWELL, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2024 financial results prior to the market open on Friday, May 3, 2024. In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m....

 PRESS RELEASE

Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from ...

Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from March 25 - 27, 2024 Company to give technical presentation on its innovative Growth Direct® Rapid Sterility Application LOWELL, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will exhibit at the 2024 Parenteral Drug Association (“PDA”) Annual Meeting from Mar...

 PRESS RELEASE

Rapid Micro Biosystems to Participate in the Virtual KeyBanc Life Scie...

Rapid Micro Biosystems to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum LOWELL, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the virtual KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024. Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are sc...

 PRESS RELEASE

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listin...

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LOWELL, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that, effective March 4, 2024, the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase 150,000 shares of the Company’s Class A common stock (...

 PRESS RELEASE

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Finan...

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance Reports fourth quarter 2023 total revenue of $6.3 million, representing 45% growth compared to fourth quarter 2022 Reports 2023 revenue of $22.5 million, representing 31% growth compared to 2022 Delivered 2023 recurring revenue of $13.5 million, representing 23% growth compared to 2022 Provides 2024 revenue guidance of at least $27.0 million, representing at least 20% growth compared to 2023 LOWELL, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasda...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch